Schrödinger, Inc. (NASDAQ:SDGR) Insider Sells $27,221.18 in Stock

Schrödinger, Inc. (NASDAQ:SDGR) insider Margaret Dugan sold 1,531 shares of the company’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $17.78, for a total transaction of $27,221.18. Following the completion of the sale, the insider now directly owns 13,469 shares of the company’s stock, valued at $239,478.82. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Schrödinger Trading Up 1.5 %

NASDAQ SDGR traded up $0.27 on Wednesday, hitting $17.92. The company’s stock had a trading volume of 481,588 shares, compared to its average volume of 747,943. The firm has a market cap of $1.30 billion, a P/E ratio of -6.69 and a beta of 1.50. Schrödinger, Inc. has a 52-week low of $16.67 and a 52-week high of $38.00. The company’s 50-day simple moving average is $19.36 and its 200 day simple moving average is $21.39.

Schrödinger (NASDAQ:SDGR) last announced its earnings results on Wednesday, July 31st. The company reported ($0.74) EPS for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.11. The company had revenue of $47.33 million during the quarter, compared to the consensus estimate of $40.19 million. Schrödinger had a negative return on equity of 38.38% and a negative net margin of 100.42%. On average, research analysts forecast that Schrödinger, Inc. will post -2.19 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on SDGR. Morgan Stanley lowered their price target on shares of Schrödinger from $43.00 to $30.00 and set an “equal weight” rating for the company in a research note on Wednesday, August 21st. Leerink Partners began coverage on Schrödinger in a research note on Tuesday, July 2nd. They issued an “outperform” rating and a $29.00 target price for the company. KeyCorp reduced their price target on Schrödinger from $30.00 to $25.00 and set an “overweight” rating on the stock in a research report on Thursday, July 11th. Finally, Leerink Partnrs upgraded Schrödinger to a “strong-buy” rating in a research report on Tuesday, July 2nd. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Schrödinger has an average rating of “Moderate Buy” and an average price target of $33.44.

Institutional Investors Weigh In On Schrödinger

Several institutional investors and hedge funds have recently modified their holdings of SDGR. Texas Permanent School Fund Corp lifted its stake in shares of Schrödinger by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 47,869 shares of the company’s stock valued at $1,292,000 after purchasing an additional 626 shares during the period. Louisiana State Employees Retirement System lifted its position in Schrödinger by 2.6% during the second quarter. Louisiana State Employees Retirement System now owns 27,800 shares of the company’s stock valued at $538,000 after buying an additional 700 shares during the period. GAMMA Investing LLC lifted its position in Schrödinger by 49.5% during the second quarter. GAMMA Investing LLC now owns 2,124 shares of the company’s stock valued at $41,000 after buying an additional 703 shares during the period. ProShare Advisors LLC boosted its holdings in shares of Schrödinger by 7.4% during the 1st quarter. ProShare Advisors LLC now owns 10,987 shares of the company’s stock valued at $297,000 after buying an additional 753 shares in the last quarter. Finally, Illinois Municipal Retirement Fund grew its position in shares of Schrödinger by 2.7% in the 1st quarter. Illinois Municipal Retirement Fund now owns 32,043 shares of the company’s stock worth $865,000 after buying an additional 831 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.